<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02624596</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-34622</org_study_id>
    <nct_id>NCT02624596</nct_id>
  </id_info>
  <brief_title>Understanding How Ketamine Brings About Rapid Improvement in OCD</brief_title>
  <acronym>MKET</acronym>
  <official_title>NMDAR Modulation As a Therapeutic Target and Probe of Neural Dysfunction in OCD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Connecticut</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand how ketamine brings about rapid improvement in&#xD;
      Obsessive-Compulsive Disorder (OCD) symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obsessive-Compulsive Disorder (OCD) is a chronic and disabling disorder that costs the&#xD;
      economy over $2 billion annually and represents a significant public health problem. This&#xD;
      study aims to build on our discovery that a potent NMDA receptor antagonist, ketamine, has&#xD;
      rapid (in hours) and robust therapeutic effects in OCD. The proposed projects test the acute&#xD;
      mechanism of action of ketamine at the level of molecules, circuits, and network synchrony to&#xD;
      determine how NMDA receptor antagonism modifies the underlying pathology of OCD to relieve&#xD;
      repetitive thoughts and behaviors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improvement in the severity of OCD symptoms as measured by the Yale-Brown Obsessive Compulsive Scale (YBOCS)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Improvement in OCD severity is measured by the YBOCS (Yale Brown Obsessive-Compulsive Scale), a gold standard measure of obsessions and compulsions. For the YBOCS the minimum units are 0 and Maximum units on the total scale are 40. The higher the number on the YBOCS, the more severe the symptoms. Response is defined as at least a 35% reduction on the YBOCS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Regional gamma-aminobutyric acid, glutamate/glutamine levels derived from 3T Magnetic Resonance Spectroscopy</measure>
    <time_frame>up to 90 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Obsessive-Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OCD patients in this arm will receive 0.5mg/kg of ketamine - one single infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>OCD patients in this arm will receive 0.045mg/kg of midazolam - one single infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>OCD patients in this arm will receive 0.5mg/kg of ketamine - one single infusion</description>
    <arm_group_label>Ketamine</arm_group_label>
    <other_name>Ketamine Hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>OCD patients in this arm will receive 0.045mg/kg of midazolam - one single infusion</description>
    <arm_group_label>Midazolam</arm_group_label>
    <other_name>Midazolam Hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for participants with OCD:&#xD;
&#xD;
          -  age 18-65&#xD;
&#xD;
          -  Primary diagnosis of OCD&#xD;
&#xD;
          -  Sufficient severity of OCD symptoms&#xD;
&#xD;
          -  ability to tolerate a treatment-free period&#xD;
&#xD;
          -  capacity to provide informed consent&#xD;
&#xD;
        Inclusion criteria for healthy controls:&#xD;
&#xD;
          -  ages 18-65&#xD;
&#xD;
          -  capacity to provide informed consent&#xD;
&#xD;
        Exclusion criteria for participants with OCD:&#xD;
&#xD;
          -  Psychiatric or medical conditions that make participation unsafe&#xD;
&#xD;
          -  pregnant or nursing females&#xD;
&#xD;
          -  concurrent use of any medications that might increase the risk of participation (e.g.&#xD;
             drug interactions)&#xD;
&#xD;
          -  presence of metallic device or dental braces&#xD;
&#xD;
        Exclusion criteria for healthy controls:&#xD;
&#xD;
          -  any current or lifetime psychiatric diagnosis&#xD;
&#xD;
          -  pregnant or nursing females&#xD;
&#xD;
          -  major medical or neurological problem&#xD;
&#xD;
          -  presence of metallic device or dental braces&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolyn I Rodriguez, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://med.stanford.edu/profiles/carolyn-rodriguez?tab=bio</url>
    <description>Stanford Medicine Faculty Page</description>
  </link>
  <link>
    <url>http://med.stanford.edu/rodriguezlab/research/ocd-research/mket-study.html</url>
    <description>Rodriguez Lab Website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 2, 2015</study_first_submitted>
  <study_first_submitted_qc>December 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2015</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Carolyn Rodriguez</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>OCD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

